Executive Summary
Pharma and biotech activity in the week ending July 13, 2026, reflected sustained dealmaking and restructuring as the first half concluded. Multiple acquisitions and financing rounds underscored Big Pharma's push to replenish pipelines ahead of patent cliffs, while selective layoffs highlighted ongoing efficiency efforts.
Regulatory developments mixed approvals momentum with setbacks, and investor interest remained focused on oncology, gene therapies, and emerging modalities. Global capital continued flowing into the sector through M&A and strategic equity deals.
Key Developments
- On July 6, Novartis agreed to acquire UK-based Myricx Bio for $1.1 billion upfront plus up to $400 million in milestones to advance antibody-drug conjugate programs in cancer.
- Also on July 6, Incyte completed the acquisition of Vega Therapeutics for up to $2 billion to expand its blood disease pipeline.
- Genentech announced 103 job cuts on July 6 as part of early development restructuring, while signing a $490 million-plus collaboration with Astex.
- Roche ended development of two Ionis-partnered Huntington’s disease programs mid-week due to efficacy and safety concerns.
- ARPA-H launched a $160 million initiative on July 9 to develop custom gene-editing therapies for rare diseases.
- Bayer secured a €3 billion equity infusion from Apollo on July 10 tied to its contraceptives business.
- The FDA issued a third rejection for a Hengrui/Elevar PD-1 liver cancer combination around July 10.
- Biosimilar adoption accelerated in the US amid approaching biologic patent expirations, with industry reports noting improving physician acceptance.
Implications for Investors
Accelerating M&A signals Big Pharma's willingness to deploy capital for de-risked assets in oncology and specialty areas, potentially supporting valuations for innovative biotechs with late-stage programs. Investors with exposure to the sector may monitor pipeline replenishment trends and their impact on revenue visibility beyond 2026 patent expirations.
Restructuring moves like Genentech's layoffs indicate cost discipline amid competitive pressures, while funding rounds and government initiatives in gene editing highlight continued innovation funding. Areas such as ADCs, biosimilars, and AI-enabled discovery could see sustained attention as modalities evolve.
Risks & Opportunities
- Regulatory setbacks, such as repeated FDA rejections, could delay launches and pressure timelines for affected programs.
- Patent cliff pressures may drive further consolidation but also increase competition for high-quality assets and valuations.
- Onshoring requirements and potential tariffs create both manufacturing investment opportunities and supply-chain cost risks for global players.
- Growing biosimilar competition offers cost-saving potential for healthcare systems but may erode margins for originator biologics.
- AI integration in drug development presents opportunities for efficiency gains while introducing new competitive dynamics from tech entrants.
Global Capital-Flow Context
Capital flows into pharma and biotech remained robust in the trailing week, driven by cross-border M&A and strategic equity infusions. Deals such as Novartis's acquisition of Myricx and Bayer's Apollo partnership illustrate continued rotation of Big Pharma cash reserves and institutional capital toward pipeline-enhancing assets, particularly in oncology and women's health.
US-focused onshoring commitments exceeding $500 billion underscore domestic manufacturing inflows, while international players navigate policy overhangs. Overall, H1 2026 deal volume trends suggest sustained investor appetite for the sector amid stabilizing policy and rate environments.